Future research objectives must concentrate on creating prediction algorithms for appropriate receptor targeting ratios, exploring triple-agonist strategies (GLP-1/GIP/glucagon), and determining long-term safety profiles for multi-receptor therapies
Now, even when Im wrong, it feels like the decision is mine and that difference matters
*Correspondence: Diego Perez-Tilve, College of Medicine/Internal Medicine, Metabolic Disease Institute, University of Cincinnati, 2180 E
309 , F2F23 (2015)
Earlier this month, data presented at the European Association for the Study of Diabetes conference showed that study participants who got a higher dose of the experimental drug amycretin lost an average of 13% of their body weight in 12 weeks
Silverii GA, Monami M, Gallo M, Ragni A, Prattichizzo F, Renzelli V, et al